Amarantus Bioscience Holdings Inc (AMBS): Neurotrope Bioscience (OTC:NTRP) has AD...

Amarantus Bioscience Holdings Inc (AMBS)

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	115
Posts	4767
Boards Moderated	0
Alias Born	07/11/2010

GS1

Re: joboggi post# 114768

Friday, 05/29/2015 5:59:23 AM

Friday, May 29, 2015 5:59:23 AM

Neurotrope Bioscience (OTC:NTRP) has AD Diagnostic test done in 140 patients with 97% S/S. The test involves punch biopsy i.e taking piece of skin and analyzing it. It is able to identify mix dimentias. Interestingly Jeff Cummings is on BOD.

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/Diagnostic_System.html

Diagnostic Division

Neurotrope also has a diagnostic test for AD that has been tested in a total of 140 individuals, including AD patients, patients with mixed dementia, patients with non-AD dementia, and healthy controls. The total also includes 51 patients with autopsy-confirmed diagnoses. Results showed sensitivity (correctly diagnosing AD) = 97% and specificity (correctly identifying individuals without AD) = 96%, both of which compare quite favorably with other published diagnostic tests.